Acarbose and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Acarbose (acarbose), especially for people who are female, 60+ old, also take Methotrexate, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Psoriasis when taking Acarbose. It is created by eHealthMe based on reports of 4,551 people who have side effects when taking Acarbose from the FDA, and is updated regularly.

What is Acarbose?

Acarbose has active ingredients of acarbose. It is often used in diabetes. eHealthMe is studying from 4,605 Acarbose users. Check the latest studies of Acarbose.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,474 drugs and 1,695 conditions by eHealthMe. Check the latest studies of Psoriasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

4,551 people reported to have side effects when taking Acarbose.
Among them, 15 people (0.33%) have Psoriasis.

Among these 15 people:

What is the gender of people who have Psoriasis when taking Acarbose? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Psoriasis when taking Acarbose? *

What are other drugs people take besides Acarbose? *

What are other side effects people have besides Psoriasis? *

Itching: 5 people, 33.33%
Rash Erythematous (redness of the skin): 5 people, 33.33%
Dermatitis Bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid): 4 people, 26.67%
Rash Pustular (redness with pustules): 3 people, 20.00%
Erythema Multiforme (a type of hypersensitivity reaction): 2 people, 13.33%
Hemiparesis (weakness on one side of the body): 1 person, 6.67%
Gallstones (stone formation by bile component): 1 person, 6.67%
Epidermal Necrolysis (skin condition that is usually caused by a reaction to drugs): 1 person, 6.67%
Drug Ineffective: 1 person, 6.67%
White Blood Cell Count Decreased: 1 person, 6.67%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 13.33%
Thyroid Diseases: 1 person, 6.67%
Arthropathy: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Acarbose and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Acarbose:

Acarbose (4,605 reports)

Psoriasis treatments and more:

Psoriasis (508,164 reports)

Browse all side effects of Acarbose:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,474 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,695 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on acarbose (the active ingredients of Acarbose) and Acarbose (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.